INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $3,665,000 | +26.8% | 30,274 | +18.5% | 0.02% | +53.8% |
| Q1 2017 | $2,890,000 | +13.7% | 25,550 | +9.2% | 0.01% | 0.0% |
| Q4 2016 | $2,541,000 | -37.7% | 23,389 | -5.6% | 0.01% | -31.6% |
| Q3 2016 | $4,079,000 | -7.6% | 24,781 | -19.9% | 0.02% | -17.4% |
| Q2 2016 | $4,415,000 | -10.4% | 30,946 | -19.3% | 0.02% | -30.3% |
| Q1 2016 | $4,929,000 | -27.8% | 38,369 | -16.1% | 0.03% | -38.9% |
| Q4 2015 | $6,829,000 | +1.5% | 45,728 | +12.7% | 0.05% | +3.8% |
| Q3 2015 | $6,727,000 | -48.2% | 40,558 | -24.6% | 0.05% | -32.5% |
| Q2 2015 | $12,976,000 | +50.5% | 53,759 | +75.9% | 0.08% | +54.0% |
| Q1 2015 | $8,620,000 | +92.2% | 30,566 | +6.3% | 0.05% | +78.6% |
| Q4 2014 | $4,485,000 | -48.8% | 28,750 | -22.3% | 0.03% | -39.1% |
| Q3 2014 | $8,755,000 | -1.1% | 36,988 | -1.1% | 0.05% | +12.2% |
| Q2 2014 | $8,852,000 | -7.9% | 37,407 | +28.3% | 0.04% | -14.6% |
| Q1 2014 | $9,615,000 | – | 29,155 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |